MRNA
Moderna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$145.55
−2.23%Year over year
Reported trailing growth
- Revenue
- -27.2%
- EBITDA
- -3.9%
- EBIT
- -1.4%
- EPS
- -6.0%
- Free cash flow
- +65.1%
- Operating cash flow
- +61.0%
Forward estimates
Based on analyst estimates
- Revenue
- -12.6%
- EBITDA
- +13.3%
- EPS
- +13.3%
Three-year CAGR
- Revenue
- -53.1%
- EBITDA
- +24.8%
- EBIT
- +22.1%
- Net income
- +20.8%
- EPS
- +21.7%
- Free cash flow
- +49.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026